Bilirubin Blood Test Market Size, Share & Trends Analysis Report By Test Type (Total Serum Bilirubin (TSB), Direct/Conjugated Bilirubin, Indirect/Unconjugated Bilirubin), By End-User (Hospitals, Diagnostic Laboratories, Ambulatory Surgical Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Bilirubin Blood Test Market Size

The global bilirubin blood test market size was valued at USD 1.3 billion in 2025 and is projected to grow from USD 1.38 billion in 2026 to USD 2.21 billion by 2034, registering a CAGR of 6.05% during the forecast period from 2026 to 2034. North America dominated the bilirubin blood test market with a market share of 38.4% in 2025.

The global market is poised for significant growth, driven by several factors that are expected to shape its future landscape. As healthcare systems globally shift towards more preventive care, the demand for accurate diagnostic tools like bilirubin blood tests is anticipated to rise. Moreover, the increasing prevalence of liver diseases, including hepatitis and cirrhosis, alongside the rising incidence of neonatal jaundice, will likely contribute to sustained market demand.

A Bilirubin Blood Test measures the levels of bilirubin, a yellow pigment produced during the breakdown of red blood cells, in the blood. This test helps evaluate liver function, as bilirubin is processed by the liver and excreted in bile. Elevated bilirubin levels can indicate liver diseases such as hepatitis and cirrhosis or conditions like gallstones or hemolytic anemia, where red blood cells break down too quickly.

The test is commonly ordered for newborns to check for jaundice, a condition where high bilirubin levels cause yellowing of the skin and eyes. In adults, it is used to diagnose and monitor liver disorders, bile duct issues, or hemolytic diseases. The results of this test provide crucial information about the liver's health and overall functioning.

Test Type Insights

The market is divided into total serum bilirubin (TSB), direct/conjugated bilirubin, and indirect/unconjugated bilirubin. The total serum bilirubin (TSB) segment is estimated to own the market over the forecast period. The total serum bilirubin (TSB) segment dominates the global market due to its widespread use in clinical settings to assess overall bilirubin levels in the blood. TSB is a crucial indicator in diagnosing and monitoring liver function, neonatal jaundice, and hemolytic disorders. Its comprehensive nature, encompassing both direct (conjugated) and indirect (unconjugated) bilirubin, makes it the preferred test among healthcare providers.

The segment's growth is driven by its essential role in routine liver function tests and neonatal screenings. Moreover, advancements in laboratory automation and point-of-care testing technologies have made TSB tests more accessible and efficient, further boosting the segment's prominence in the market.

Request Customizationto receive a tailored report.

End-User Insights

The market is segmented into hospitals, diagnostic laboratories, ambulatory surgical centers, and others. The hospital segment dominated the market during the forecast period. The hospital segment accounted for a substantial share due to the high volume of bilirubin tests performed in these settings. Hospitals are the primary care providers for neonatal jaundice, liver diseases, and other conditions requiring regular bilirubin monitoring. The availability of advanced diagnostic equipment, such as automated analyzers and point-of-care devices, enhances the efficiency of bilirubin testing in hospitals.

Additionally, the presence of specialized neonatal intensive care units (NICUs) in hospitals further drives the demand for bilirubin testing, particularly for newborns at risk of hyperbilirubinemia. This segment's dominance is expected to continue as hospitals remain central to acute and chronic bilirubin monitoring.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global market shareholder and is expected to expand substantially over the forecast period. The North American bilirubin blood test market holds a prominent position globally, driven by advanced healthcare infrastructure, high awareness levels, and the prevalence of liver-related diseases. According to the Centers for Disease Control and Prevention (CDC), liver disease is a major health concern in the U.S., affecting nearly 4.5 million adults.

Similarly, as per the Canadian Liver Foundation estimates, liver disease may impact one in four Canadians and cause 5,000 deaths annually in the country. This surging burden of liver diseases is estimated to foster the demand for bilirubin blood tests in this region. Moreover, the widespread adoption of cutting-edge diagnostic technologies, such as point-of-care testing devices, further accelerates the market growth in this region.

Unlock Regional Insightsto access country-level data, & regional trends.

United States Bilirubin Blood Test Market Trends

In the United States, the market is experiencing robust growth due to several factors, including the increasing prevalence of liver diseases and the high incidence of neonatal jaundice. Approximately 3,000 babies in the U.S. suffer from severe jaundice annually, according to the American Academy of Pediatrics. This high incidence rate drives the demand for frequent bilirubin testing in newborns.

Moreover, the U.S. healthcare system's focus on early diagnosis and treatment of liver conditions contributes to the market's expansion. The country is also home to major market players like Abbott Laboratories and Thermo Fisher Scientific, which invest heavily in research and development to introduce advanced bilirubin testing solutions. These factors, combined with a well-established healthcare infrastructure, position the U.S. as the dominant player in the North American bilirubin blood test market.

The Asia-Pacific region is poised to witness significant growth. The region's market growth is driven by factors such as the rising birth rate, increasing prevalence of liver diseases, and expanding healthcare infrastructure. Countries like India, China, and Japan are leading the region, with a growing focus on improving neonatal care and early diagnosis of liver conditions. The Asia-Pacific market is also benefiting from increased government initiatives and international support aimed at enhancing maternal and child health.

• For instance, programs supported by organizations like UNICEF are promoting routine bilirubin screening to prevent complications like neonatal jaundice.

China is emerging as a key player in the Asia-Pacific bilirubin blood test market, driven by its large neonatal population and increasing healthcare investments. In 2022, China's birth rate was approximately 10.41 births per 1,000 people, highlighting the need for robust neonatal care. The country's healthcare system has seen significant improvements, with the government prioritizing maternal and child health.

Similarly, China's growing middle class is increasingly seeking high-quality healthcare services, including advanced diagnostic tests. The Chinese government's Healthy China 2030 initiative, which focuses on improving healthcare access and quality, is expected to further drive the demand for bilirubin blood tests, positioning China as a critical market in the region.

List of Key and Emerging Players in Bilirubin Blood Test Market